EXHIBIT 10.3

                         COST AND EVALUATION AGREEMENT







AHPharma, Inc.                                        James L. McNaughton, Ph.D.
Food Safety & Animal Health Firm                        Chief Scientific Officer
                                                  Email: McNaughton@AHPharma.com


                       POULTRY SALMONELLA VACCINE PROJECT
                          COST AND EVALUATION AGREEMENT
                      GLOBAL GREEN, Inc. and AHPharma, Inc.
                                  JULY 30, 2011


         As mentioned  in the initial  Executive  Summary,  GLOBAL  GREEN,  Inc.
Vaccine USDA/FSIS regulatory approval is required.  Generally, vaccine approvals
are relatively  easier,  less  cumbersome  and require much less  scrutiny,  and
therefore,   less  cost  than  with  either  FDA  or  EPA  regulatory   approval
requirements.

The entire project anticipated time frame includes:

     -    Final product evaluation of GLOBAL GREEN, Inc. GMP (Good Manufacturing
          Practice,  21 CFR  Part  110)  material  obtained  from  GLOBAL  GREEN
          (4-months required).
     -    Final vaccine product manufacturing (~8-12 months required).
     -    Approval  time frame,  including  regulatory  approval and  commercial
          field-testing (3 locations), we anticipate a 12-18 month time frame is
          required.
     -    Consequently,  the total  timeframe is anticipated to be 12-18 months,
          barring any  unforeseen  circumstances  that may be out of our control
          from either USDA/FSIS or the vaccine manufacturer.

         Time frame variables  include:  time required for GLOBAL GREEN, Inc. to
produce   GMP   material,   chosen   manufacturing   workload/production   space
availability,  and  regulatory  agency  responses.  Typically,  with a  vaccine,
AHPharma's  experience has been that vaccine  regulatory  agencies are extremely
responsive and  infrequently  delays the process.  AHPharma testing periods will
NOT be delayed and posed no treat to timing schedules. Anticipated time does not
include GLOBAL GREEN's time required to produce the final GMP material.

Project cost includes:

     -    Final   product   evaluation   of   GMP   material
          anticipated  cost.  A "Mock  Study" will be tested
          against  Salmonella  field strains  throughout the
          USA (at least three different locations and States
          in three different regions).                                  $ 60,000

     -    Final  Marek's  interference  study  on the  final
          product                                                         20,000

     -    Final vaccine  product  manufacturing  anticipated
          cost (i.e., working with the manufacturer).                     60,000

     -    Regulatory   approval   and   field   testing   (3
          locations) anticipated cost                                    160,000
                                                                       ---------
                TOTAL                                                  $ 300,000



--------------------------------------------------------------------------------
AHPharma, Inc.            Office Phone: 443-260-2499           Fax: 443-260-2476
            Mailing Address: P.O. Box 3467, Salisbury, Maryland 21802
       Shipping Address: 116 W. Chestnut Street, Salisbury, Maryland 21801



AHPharma, Inc.                                        James L. McNaughton, Ph.D.
Food Safety & Animal Health Firm                        Chief Scientific Officer
                                                  Email: McNaughton@AHPharma.com



         Cost does not include the GLOBAL  GREEN's  cost of  development  of GMP
material,  actual  manufacturing  cost,  initial  batch-size field test material
and/or  production  cost.  GMP  guidelines  are  necessary to assure  regulatory
agencies  of the  ability to create  reproducible  products,  assure  consistent
manufacturing  practices,  maintain  appropriate  record-keeping,  ensure proper
storage, assure proper sanitation practices, etc. The vaccine manufacturing site
that is chosen must have the ability to work under the guidelines of GMP.

DISCLAIMER:  Based on historical experience,  AHPharma has attempted to evaluate
and anticipate ALL costs involved in obtaining final regulatory approval. Should
USDA require  additional data collection,  outside what is anticipated,  factors
outside the control of either GLOBAL GREEN or AHPharma arise,  additional  funds
will be required to finish the final approval  process.  Until we obtain a final
bid from the product  manufacturer,  final manufacturing  initial cost cannot be
fully  finalized  and is the cost area that may  potential  change.  Anticipated
regulatory  approval  cost is a reasonably  safe cost.  At this time,  we do not
anticipate that additional funds will be required.


AHPharma, Inc.                              GLOBAL GREEN, Inc.


---------------------------                 ---------------------------
James L. McNaughton, Ph.D.                  Mehran Ghazvini, DC, NMD, CEO
President & CEO                             CEO of Global Green, Inc.

----------------------------                ----------------------------
Date                                        Date




















--------------------------------------------------------------------------------
AHPharma, Inc.             Office Phone: 443-260-2499          Fax: 443-260-2476
            Mailing Address: P.O. Box 3467, Salisbury, Maryland 21802
       Shipping Address: 116 W. Chestnut Street, Salisbury, Maryland 21801